US Patent

US9295687 — Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Formulation · Assigned to Medicines Co · Expires 2035-07-10 · 9y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical formulations containing high purity cangrelor, an active ingredient used to inhibit platelet activation and aggregation.

USPTO Abstract

The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Drugs covered by this patent

Patent Metadata

Patent number
US9295687
Jurisdiction
US
Classification
Formulation
Expires
2035-07-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Medicines Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.